Menu
Search
|

Menu

Close
X

Neuralstem Inc CUR.OQ (NASDAQ Stock Exchange Capital Market)

1.52 USD
-0.04 (-2.24%)
As of Feb 23
chart
Previous Close 1.56
Open 1.55
Volume 9,880
3m Avg Volume 187,525
Today’s High 1.55
Today’s Low 1.49
52 Week High 6.58
52 Week Low 0.89
Shares Outstanding (mil) 15.15
Market Capitalization (mil) 23.10
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.079
FY16
-2.576
FY15
-2.988
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
1,421.40
8.35
Price to Book (MRQ)
vs sector
2.00
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
0.00
15.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-237.37
13.63
Return on Equity (TTM)
vs sector
-456.80
15.39

EXECUTIVE LEADERSHIP

Richard Daly
Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial and Accounting Officer, Since 2017
Salary: --
Bonus: --
David Recker
Chief Medical Officer, Since 2017
Salary: --
Bonus: --
Xi Chen
Director, Since 2017
Salary: --
Bonus: --
Cristina Csimma
Director, Since 2017
Salary: --
Bonus: --
Scott Ogilvie
Independent Director, Since 2008
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

20271 Goldenrod Ln
GERMANTOWN   MD   20876-4064

Phone: +1301.3664841

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

SPONSORED STORIES